Beutel Goodman & Co Ltd. Reduces Stake in Johnson & Johnson $JNJ

Beutel Goodman & Co Ltd. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 5.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,781 shares of the company’s stock after selling 2,495 shares during the quarter. Beutel Goodman & Co Ltd.’s holdings in Johnson & Johnson were worth $6,534,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GFG Capital LLC purchased a new position in Johnson & Johnson in the second quarter valued at $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at $48,000. Vermillion & White Wealth Management Group LLC boosted its stake in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares during the last quarter. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter worth $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $202.24 on Friday. The firm has a 50 day simple moving average of $193.61 and a 200-day simple moving average of $174.90. The stock has a market cap of $487.25 billion, a price-to-earnings ratio of 19.52, a price-to-earnings-growth ratio of 2.29 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $207.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Bank of America raised their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Citigroup boosted their target price on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $202.10.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.